22 Updated Revised Milestones/Opportunities Ly
Post# of 30028
Posted On: 09/06/2014 1:56:06 PM
22 Updated Revised Milestones/Opportunities
LymPro Test®
01.) LymPro Test® - LP-002 data (Sept.)
02.) LymPro Test® - JV Partner (by 4Q14)
03.) LymPro Test® - updates on studies for TBI/CTE
Eltoprazine
04.) Eltoprazine - signif. announcements, incl. 200 patient Ph. 2b trial (by 4Q14)
MANF
05.) MANF - Ophthalmological toxicology complete data sets (by 4Q14)
06.) MANF RP - functional data & addit. efficacy data sets (by 4Q14)
07.) MANF / GDNF - Renishaw Ph. 2B test trial results (est. 4Q14)
08.) potential - MANF RP orphan (est. Sept.)
09.) potential - MANF DB-1 Wolframs orphan (est. 4Q14)
10.) potential - MANF - additional data from undisclosed activities
11.) potential business development activity around the MANF program
PhenoGuard
12.) potential - active PhenoGuard JV Partnership update
13.) portential - discovery of another such protein family would (cont. into #13)
14. ) potential - transform PhenoGuard into first ever rationally-designed neurotrophic factor discovery platform
15.) potential - evaluation of external drug candidates for potential in-licensure or
16.) potential - acquisition
NuroPro® Blood Test
17.) potential - Diagnostics Div. spin out
18.) Amarantus is preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
P16
19.) possibility of a "targeted therapeutic" on those Alzheimer's patients that have tested positive for LymPro Test®
General Business Opportunities
20.) potential - financial engineering (by 9/22 ASM)
21.) potential - grant funding (application count of 6 so far)
22.) potential - white paper
LymPro Test®
01.) LymPro Test® - LP-002 data (Sept.)
02.) LymPro Test® - JV Partner (by 4Q14)
03.) LymPro Test® - updates on studies for TBI/CTE
Eltoprazine
04.) Eltoprazine - signif. announcements, incl. 200 patient Ph. 2b trial (by 4Q14)
MANF
05.) MANF - Ophthalmological toxicology complete data sets (by 4Q14)
06.) MANF RP - functional data & addit. efficacy data sets (by 4Q14)
07.) MANF / GDNF - Renishaw Ph. 2B test trial results (est. 4Q14)
08.) potential - MANF RP orphan (est. Sept.)
09.) potential - MANF DB-1 Wolframs orphan (est. 4Q14)
10.) potential - MANF - additional data from undisclosed activities
11.) potential business development activity around the MANF program
PhenoGuard
12.) potential - active PhenoGuard JV Partnership update
13.) portential - discovery of another such protein family would (cont. into #13)
14. ) potential - transform PhenoGuard into first ever rationally-designed neurotrophic factor discovery platform
15.) potential - evaluation of external drug candidates for potential in-licensure or
16.) potential - acquisition
NuroPro® Blood Test
17.) potential - Diagnostics Div. spin out
18.) Amarantus is preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
P16
19.) possibility of a "targeted therapeutic" on those Alzheimer's patients that have tested positive for LymPro Test®
General Business Opportunities
20.) potential - financial engineering (by 9/22 ASM)
21.) potential - grant funding (application count of 6 so far)
22.) potential - white paper
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼